Skip to main content
Livermore
Livermore
ZHEN

Vanguard Group Inc

SEC CIK
0000102909
Latest filing
Jan 29, 2026

YMAB holding history

Y-mAbs Therapeutics, Inc. in every 13F filed by Vanguard Group Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

YMAB overviewAll 13F holders of YMABFull Q4 2025 holdings

Shares (Q3 2025)
0
Sold out in Q3 2025
Value
$0
% of portfolio
0.0%
Quarters held
18
Since Q1 2021
Holdings of YMAB by Vanguard Group Inc, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q3 20250$00.0%−1,943,285−100.0%Sold outHolders
Q2 20251,943,285$8.76M<0.1%−3,224−0.2%ReducedHolders
Q1 20251,946,509$8.62M<0.1%−53,513−2.7%ReducedHolders
Q4 20242,000,022$15.7M<0.1%−35,341−1.7%ReducedHolders
Q3 20242,035,363$26.8M<0.1%+78,024+4.0%AddedHolders
Q2 20241,957,339$23.6M<0.1%−112,178−5.4%ReducedHolders
Q1 20242,069,517$33.7M<0.1%−174,721−7.8%ReducedHolders
Q4 20232,244,238$15.3M<0.1%+12,330+0.6%AddedHolders
Q3 20232,231,908$12.2M<0.1%+4,899+0.2%AddedHolders
Q2 20232,227,009$15.1M<0.1%−53,993−2.4%ReducedHolders
Q1 20232,281,002$11.4M<0.1%+22,748+1.0%AddedHolders
Q4 20222,258,254$11.0M<0.1%+337,833+17.6%AddedHolders
Q3 20221,920,421$27.7M<0.1%−9,495−0.5%ReducedHolders
Q2 20221,929,916$29.2M<0.1%+135,406+7.5%AddedHolders
Q1 20221,794,510$21.3M<0.1%−22,564−1.2%ReducedHolders
Q4 20211,817,074$29.5M<0.1%+13,150+0.7%AddedHolders
Q3 20211,803,924$51.5M<0.1%+168,669+10.3%AddedHolders
Q2 20211,635,255$55.3M<0.1%+36,676+2.3%AddedHolders
Q1 20211,598,579$48.3M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.